Iovance Biotherapeutics Statistics Share Statistics Iovance Biotherapeutics has 333.93M
shares outstanding. The number of shares has increased by 10.02%
in one year.
Shares Outstanding 333.93M Shares Change (YoY) 10.02% Shares Change (QoQ) 1.85% Owned by Institutions (%) 74.17% Shares Floating 294.19M Failed to Deliver (FTD) Shares 65,918 FTD / Avg. Volume 0.34%
Short Selling Information The latest short interest is 98.63M, so 29.54% of the outstanding
shares have been sold short.
Short Interest 98.63M Short % of Shares Out 29.54% Short % of Float 32.35% Short Ratio (days to cover) 7.21
Valuation Ratios The PE ratio is -5.76 and the forward
PE ratio is -2.97.
Iovance Biotherapeutics's PEG ratio is
0.18.
PE Ratio -5.76 Forward PE -2.97 PS Ratio 13.07 Forward PS 1.6 PB Ratio 3.02 P/FCF Ratio -5.89 PEG Ratio 0.18
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Iovance Biotherapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 3.74,
with a Debt / Equity ratio of 0.08.
Current Ratio 3.74 Quick Ratio 3.31 Debt / Equity 0.08 Debt / EBITDA -0.17 Debt / FCF -0.16 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $195.79K Profits Per Employee $-444.13K Employee Count 838 Asset Turnover 0.18 Inventory Turnover 2.41
Taxes Income Tax -2.83M Effective Tax Rate 0.75%
Stock Price Statistics The stock price has increased by -80.48% in the
last 52 weeks. The beta is 0.88, so Iovance Biotherapeutics's
price volatility has been higher than the market average.
Beta 0.88 52-Week Price Change -80.48% 50-Day Moving Average 2.22 200-Day Moving Average 4.94 Relative Strength Index (RSI) 42.29 Average Volume (20 Days) 19,137,652
Income Statement In the last 12 months, Iovance Biotherapeutics had revenue of 164.07M
and earned -372.18M
in profits. Earnings per share was -1.28.
Revenue 164.07M Gross Profit 40.08M Operating Income -395.28M Net Income -372.18M EBITDA -351.67M EBIT -395.28M Earnings Per Share (EPS) -1.28
Full Income Statement Balance Sheet The company has 115.69M in cash and 58.26M in
debt, giving a net cash position of 57.43M.
Cash & Cash Equivalents 115.69M Total Debt 58.26M Net Cash 57.43M Retained Earnings -2.38B Total Assets 966.74M Working Capital 389.96M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -352.98M
and capital expenditures -11.07M, giving a free cash flow of -364.05M.
Operating Cash Flow -352.98M Capital Expenditures -11.07M Free Cash Flow -364.05M FCF Per Share -1.26
Full Cash Flow Statement Margins Gross margin is 24.43%, with operating and profit margins of -240.92% and -226.84%.
Gross Margin 24.43% Operating Margin -240.92% Pretax Margin -228.56% Profit Margin -226.84% EBITDA Margin -214.34% EBIT Margin -240.92% FCF Margin -221.88%
Dividends & Yields IOVA does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for IOVA is $12,
which is 509.1% higher than the current price. The consensus rating is "Buy".
Price Target $12 Price Target Difference 509.1% Analyst Consensus Buy Analyst Count 11
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Sep 26, 2013. It was a
backward
split with a ratio of 1:100.
Last Split Date Sep 26, 2013 Split Type backward Split Ratio 1:100
Scores Altman Z-Score -2.18 Piotroski F-Score 4
